AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6382932 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 4
Study 6382932 — intervention group
Group type: COMPARATOR
Intervention: Ionic media
Number of subjects: 4
Study 31029516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14)
Number of subjects: 30
Study 31029516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/CNI group
Number of subjects: 30
Study 31029516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/MMF group
Number of subjects: 30
Study 28614627 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention (n‐3 polyunsaturated fatty acid nutritional supplements, exercise, and anti‐inflammatory medication: celecoxib)
Number of subjects: 46
Study 28614627 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study 28614627 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention
Number of subjects: 46
Study 25848235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking group)
Number of subjects: 102
Study 25848235 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory training (breathing group)
Number of subjects: 102
Study 25848235 — intervention group
Group type: COMPARATOR
Intervention: Social interaction (control group)
Number of subjects: 102
Study 23718152 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted decolonization (screening, isolation, and decolonization of MRSA carriers)
Number of subjects: 74256
Study 23718152 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization (no screening, and decolonization of all patients)
Number of subjects: 74256
Study 23718152 — intervention group
Group type: COMPARATOR
Intervention: Screening and isolation (MRSA screening and isolation)
Number of subjects: 74256
Study 22231004 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with 0.12% chlorhexidine gluconate (Periogard®) mouthrinses twice a week
Number of subjects: 34
Study 22231004 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing with fluoride dentifrice (control)
Number of subjects: 34
Study 19124701 — intervention group
Group type: EXPERIMENTAL
Intervention: Single physician e-mail intervention
Number of subjects: 190
Study 19124701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 17876019 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise training
Number of subjects: 251
Study 17876019 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 251
Study 17876019 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and lipid values
Number of subjects: 251
Study 15523457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound testing in patients with migraine-related dizziness
Number of subjects: 19
Study 15523457 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Doppler ultrasound testing in control patients (no history of migraine or dizziness)
Number of subjects: 19
Study 11831621 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein measurement
Number of subjects: 0
Study 11831621 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment strategies for atheroma
Number of subjects: 0
Study 9758029 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (n=386): specially trained nurses providing extra time to explain prognoses and treatments
Number of subjects: 717
Study 9758029 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=331)
Number of subjects: 717
Study 8641505 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) treatment
Number of subjects: 41
Study 8641505 — intervention group
Group type: COMPARATOR
Intervention: No preoperative medical treatment
Number of subjects: 41
Study 2149913 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (DG)
Number of subjects: 54
Study 2149913 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene (GD)
Number of subjects: 54
Study 2149913 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study 6795050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pentagastrin injection in normal male subjects
Number of subjects: 0
Study 6795050 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of pentagastrin
Number of subjects: 0
Study 6795050 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of gastrin secretion by a protein test meal
Number of subjects: 0
Study 6795050 — intervention group
Group type: COMPARATOR
Intervention: Intragastric administration of a calcium chloride solution
Number of subjects: 0
Study 31558323 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP‐A (web‐based survivorship care plan application)
Number of subjects: 165
Study 31558323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 30776572 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cigarette Evaluation Questionnaire (mCEQ) Satisfaction subscale
Number of subjects: 169
Study 30776572 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cigarette Evaluation Questionnaire (mCEQ) Enjoyment of Respiratory Tract Sensations subscale
Number of subjects: 169
Study 30776572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette Purchase Task (CPT) Elasticity index
Number of subjects: 169
Study 29065142 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B boost (fourth dose)
Number of subjects: 13
Study 26835542 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 261
Study 26835542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 24912179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 24
Study 24912179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22718547 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25mg pramipexole
Number of subjects: 46
Study 22718547 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg clonazepam
Number of subjects: 46
Study 22718547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20145345 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day) with clopidogrel (75 mg/day)
Number of subjects: 20
Study 20145345 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day) alone (placebo)
Number of subjects: 20
Study 17919378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cattle encephalon glycoside and ignotin injection (20 ml after induction of anesthesia)
Number of subjects: 40
Study 17919378 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 15673424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose solution
Number of subjects: 0
Study 15673424 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12540322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 12540322 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9447396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II screening test
Number of subjects: 0
Study 7963387 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural block (IPB) with 10 ml of 1% lidocaine
Number of subjects: 17
Study 7963387 — intervention group
Group type: COMPARATOR
Intervention: Epidural block (EB) with 10 ml of 1% lidocaine
Number of subjects: 17
Study 3298360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous APSAC, 30 mg (n = 16)
Number of subjects: 40
Study 3298360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study 31996139 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position (20°) for 24 hours postoperatively
Number of subjects: 101
Study 31996139 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care in supine head up position
Number of subjects: 101
Study 29371383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 14 days on/off
Number of subjects: 416
Study 29371383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 28 days on/off
Number of subjects: 416
Study 29371383 — intervention group
Group type: COMPARATOR
Intervention: Placebo 14 days on/off
Number of subjects: 416
Study 29371383 — intervention group
Group type: COMPARATOR
Intervention: Placebo 28 days on/off
Number of subjects: 416
Study 27629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery combined with corpus callosotomy (CCT)
Number of subjects: 68
Study 27629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively resective surgery
Number of subjects: 68
Study 27629372 — intervention group
Group type: COMPARATOR
Intervention: Medicine (medicine group)
Number of subjects: 68
Study 27629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery combined with CCT
Number of subjects: 68
Study 24961325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovasculogen (plasmid genetic construction containing human gene VEGF165) at a course dose of 2.4 mg
Number of subjects: 100
Study 24961325 — intervention group
Group type: COMPARATOR
Intervention: Conventional vascular therapy
Number of subjects: 100
Study 22429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion at 1.0‐4.0 μg/kg per h
Number of subjects: 41
Study 22429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 41
Study 22429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion >2.0 μg/kg per h during the preanhepatic phase
Number of subjects: 41
Study 22429362 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (generally accepted inotropic and vasopressor agents)
Number of subjects: 41
Study 20407429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraductal ultrasonography (IDUS)
Number of subjects: 40
Study 20407429 — intervention group
Group type: COMPARATOR
Intervention: Other imaging methods without IDUS
Number of subjects: 40
Study 20407429 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive IPMN with preoperative IDUS
Number of subjects: 40
Study 20407429 — intervention group
Group type: COMPARATOR
Intervention: Other imaging methods for invasive IPMN
Number of subjects: 40
Study 20407429 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive IPMN
Number of subjects: 40
Study 20407429 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 40
Study 18757528 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation
Number of subjects: 100
Study 18757528 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 100
Study 18757528 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication
Number of subjects: 100
Study 18757528 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional communication with physicians
Number of subjects: 100
Study 16311183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual (SL) liquid buprenorphine
Number of subjects: 57
Study 16311183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual (SL) tablet buprenorphine
Number of subjects: 57
Study 12425406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid augmentation during the first 36 hours after surgery
Number of subjects: 166
Study 12425406 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative replacement fluids
Number of subjects: 166
Study 10353976 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-applied EMLA
Number of subjects: 41
Study 10353976 — intervention group
Group type: COMPARATOR
Intervention: Clinician-applied EMLA
Number of subjects: 41
Study 8678366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologically organ-confined cancer
Number of subjects: 0
Study 8678366 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specimen-confined prostate cancer
Number of subjects: 0
Study 8678366 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 8678366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer that has spread through the capsule
Number of subjects: 0
Study 1892146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg every 12 hours, administered orally or by nasogastric tube
Number of subjects: 147
Study 1892146 — intervention group
Group type: COMPARATOR
Intervention: Usual care (individual investigator's best selection of therapy administered parenterally)
Number of subjects: 147
Study 6660930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 54
Study 6660930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin infusion
Number of subjects: 54
Study 6660930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by i.v. oxytocin
Number of subjects: 54
Study 6660930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by another dose of PGE2-gel and subsequent i.v. oxytocin
Number of subjects: 54
Study 30850409 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal PrEP offer following standardised counselling (10 clinics)
Number of subjects: 4000
Study 30850409 — intervention group
Group type: COMPARATOR
Intervention: Risk screening with partner self‐test option (Targeted arm, 10 clinics)
Number of subjects: 4000
Study 29905617 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline publication period
Number of subjects: 326993
Study 29905617 — intervention group
Group type: COMPARATOR
Intervention: Preguideline period
Number of subjects: 326993
Study 29905617 — intervention group
Group type: EXPERIMENTAL
Intervention: Postguideline period
Number of subjects: 326993
Study 27993166 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (twice-weekly voice messages about diabetes prevention and control)
Number of subjects: 96
Study 27993166 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community group intervention (monthly group meetings for men and women to address diabetes issues)
Number of subjects: 96
Study 27993166 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 96
Study 25262125 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 443
Study 25262125 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents
Number of subjects: 443
Study 22188557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (2.5 g)
Number of subjects: 24
Study 22188557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (5.0 g)
Number of subjects: 24
Study 22188557 — intervention group
Group type: COMPARATOR
Intervention: 1.62% testosterone gel (2.5 g) with t-shirt
Number of subjects: 24
Study 22188557 — intervention group
Group type: COMPARATOR
Intervention: 1.62% testosterone gel (any dose) with washing
Number of subjects: 24
Study 22188557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (upper arms/shoulders application site)
Number of subjects: 24
Study 22188557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (any dose)
Number of subjects: 24
Study 20406865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home ultraviolet B phototherapy
Number of subjects: 196
Study 20406865 — intervention group
Group type: COMPARATOR
Intervention: Outpatient ultraviolet B phototherapy
Number of subjects: 196
Study 17696483 — intervention group
Group type: EXPERIMENTAL
Intervention: Organically grown apples
Number of subjects: 6
Study 17696483 — intervention group
Group type: COMPARATOR
Intervention: Conventionally grown apples
Number of subjects: 6
Study 15705646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted exercise (F)
Number of subjects: 9
Study 15705646 — intervention group
Group type: COMPARATOR
Intervention: CHO exercise (CHO)
Number of subjects: 9
Study 11976158 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 11
Study 11976158 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain diet
Number of subjects: 11
Study 9799202 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 49
Study 9799202 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 49
Study 9799202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic (HC) subjects
Number of subjects: 49
Study 7614530 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF CC 30 mg daily
Number of subjects: 228
Study 7614530 — intervention group
Group type: COMPARATOR
Intervention: NIF GITS 30 mg daily
Number of subjects: 228
Study 7614530 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF GITS 60 mg daily
Number of subjects: 228
Study 7614530 — intervention group
Group type: COMPARATOR
Intervention: NIF CC 60 mg daily
Number of subjects: 228
Study 2575719 — intervention group
Group type: EXPERIMENTAL
Intervention: remoxipride
Number of subjects: 29
Study 2575719 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 29
Study 341942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 47
Study 341942 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 47
Study 341942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31856791 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity platform (ActivOnline) for 12 weeks
Number of subjects: 0
Study 31856791 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29065653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical goniometer (MGR)
Number of subjects: 30
Study 29065653 — intervention group
Group type: COMPARATOR
Intervention: Motion analysis system (MAS)
Number of subjects: 30
Study 25838290 — intervention group
Group type: COMPARATOR
Intervention: PCV10
Number of subjects: 0
Study 25838290 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 23686821 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 40mg administered subcutaneously three times weekly (tiw) for 12 months
Number of subjects: 1404
Study 23686821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study 21518294 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 91
Study 21518294 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam patching
Number of subjects: 91
Study 21518294 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-approximation plus gelfoam patching
Number of subjects: 91
Study 19592823 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enhanced practice (TEP) model
Number of subjects: 0
Study 19592823 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered by home care nurses
Number of subjects: 0
Study 16818541 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-intervention program consisting of 8 sessions before discharge and 4 home visits by specially trained nurses.
Number of subjects: 214
Study 16818541 — intervention group
Group type: COMPARATOR
Intervention: Preterm control group (no intervention).
Number of subjects: 214
Study 16818541 — intervention group
Group type: COMPARATOR
Intervention: Term control group (no intervention).
Number of subjects: 214
Study 14971626 — intervention group
Group type: EXPERIMENTAL
Intervention: Siberian ginseng
Number of subjects: 96
Study 14971626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 10757252 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg)
Number of subjects: 15
Study 10757252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 15
Study 10757252 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 15
Study 10757252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9323616 — intervention group
Group type: COMPARATOR
Intervention: RV3 rotavirus vaccine (1 mL oral dose, 6.5 x 10(5) FFU/mL)
Number of subjects: 30
Study 7870966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.003 mg/kg
Number of subjects: 7
Study 7870966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.007 mg/kg
Number of subjects: 7
Study 7870966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 0.02 mg/kg
Number of subjects: 7
Study 7870966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ)
Number of subjects: 7
Study 3759744 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 8
Study 3759744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31427872 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT‐R (running HIIT)
Number of subjects: 15
Study 31427872 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT‐F (functional HIIT)
Number of subjects: 15
Study 29949873 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (2.5 g once daily for 12 weeks)
Number of subjects: 85
Study 29949873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27926473 — intervention group
Group type: EXPERIMENTAL
Intervention: 75g oral glucose load (OGTT)
Number of subjects: 22
Study 27926473 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting
Number of subjects: 22
Study 27926473 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich meal
Number of subjects: 22
Study 27926473 — intervention group
Group type: COMPARATOR
Intervention: Fat-rich meal
Number of subjects: 22
Study 27926473 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT in severely obese patients pre- and post-bariatric surgery
Number of subjects: 22
Study 24766747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2 D levels
Number of subjects: 300
Study 24766747 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-OH levels
Number of subjects: 300
Study 24766747 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver and respiratory co-morbidity
Number of subjects: 300